Detalhe da pesquisa
1.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
N Engl J Med
; 389(1): 33-44, 2023 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37407001
2.
Degraders upgraded: the rise of PROTACs in hematological malignancies.
Blood
; 143(13): 1218-1230, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38170175
3.
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
Blood
; 143(8): 673-684, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37883795
4.
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Blood
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38662991
5.
JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
Genes Dev
; 32(11-12): 849-864, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29907650
6.
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Blood
; 142(8): 687-699, 2023 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37390310
7.
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Blood
; 142(23): 1960-1971, 2023 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647654
8.
Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib.
Br J Haematol
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634256
9.
Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study.
Br J Haematol
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38632873
10.
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blood
; 139(8): 1198-1207, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34469514
11.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood
; 140(8): 839-850, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35605176
12.
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
Blood
; 140(20): 2127-2141, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35709339
13.
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Blood
; 140(17): 1907-1916, 2022 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35789260
14.
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Blood
; 140(11): 1229-1253, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653592
15.
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
Am J Hematol
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700035
16.
Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
Br J Haematol
; 201(3): 502-509, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37015002
17.
How I treat chronic lymphocytic leukemia after venetoclax.
Blood
; 138(5): 361-369, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33876212
18.
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
Blood
; 138(10): 836-846, 2021 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34115103
19.
Marginal zone lymphoma: 2023 update on diagnosis and management.
Am J Hematol
; 98(10): 1645-1657, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37605344
20.
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Am J Hematol
; 98(3): 449-463, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36594167